Ohashi Y, Ito K, Nishi I, Kanko T, Nakao I, Nomura C, Aoki H, Saito T
Dept. Int. Med., Cancer Institute Hospital.
Gan To Kagaku Ryoho. 1990 Mar;17(3 Pt 2):475-81.
Lymphocyte subsets measured by Ortho-mune on OKT 3, OKT 4A, OKT 8, OKT 10, OKT 11, OKM1, OKB 7, OKB 2 and OKDR were observed before and after chemotherapy on patients with gastrointestinal, lung and hematopoietic malignancies. Almost all patients showed decreased T-cell function expressed by OKT 11 or OKT 3 and suppressor, helper T-cell function expressed by OKT 8 and OKT 4A. In some patients improvement of T-cell function were observed with clinical response and in such cases life span seemed to be longer as expected, and it is supposed that during cancer chemotherapy improvement of T-cell function expressed by OKT series may be important prognostic factors.
通过Ortho-mune检测OKT 3、OKT 4A、OKT 8、OKT 10、OKT 11、OKM1、OKB 7、OKB 2和OKDR淋巴细胞亚群,观察了胃肠道、肺和血液系统恶性肿瘤患者化疗前后的情况。几乎所有患者OKT 11或OKT 3所表达的T细胞功能以及OKT 8和OKT 4A所表达的抑制性、辅助性T细胞功能均降低。部分患者随着临床反应T细胞功能有所改善,在这些情况下,生存期似乎比预期更长,推测在癌症化疗期间OKT系列所表达的T细胞功能改善可能是重要的预后因素。